However, few medicines are approved for ATTR-wt. GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will ...

ATTR-CM is a heart disease that is often undiagnosed and can be fatal. Dr. James Ampadu, a cardiologist with Prisma Health, shares symptoms of ATTR-CM. Ian, who was diagnosed with ATTR-CM, also shares ...

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

The first is known as hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy and the second is known as transthyretin amyloid cardiomyopathy (ATTR-CM). Amvuttra is an ...

In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup ...

The drug, branded as Attruby in the U.S. and BEYONTTRA in Europe, showed rapid and sustained benefits for both variant and wild-type ATTR-CM patients, with noticeable improvements as early as ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. And now, the Massachusetts ...

The results from the analysis underscore the rapid and sustained benefits of vutrisiran in treating ATTR-CM across key endpoints: ...